Does the Patent Linkage System Prolong Effective Market Exclusivity? Recent Evidence From the Korea-US Free Trade Agreement in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Son, Kyung-Bok | - |
dc.contributor.author | Bae, SeungJin | - |
dc.contributor.author | Lee, Tae-Jin | - |
dc.date.accessioned | 2023-08-16T07:45:24Z | - |
dc.date.available | 2023-08-16T07:45:24Z | - |
dc.date.issued | 2019-04 | - |
dc.identifier.issn | 0020-7314 | - |
dc.identifier.issn | 1541-4469 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/114211 | - |
dc.description.abstract | This study evaluated the effect of the patent linkage system, fully introduced by the Korea-U.S. Free Trade Agreement in 2015, on patent challenges and the effective market exclusivity of new medicines in Korea. We used pharmaceutical approval data and pharmaceutical litigation data to detect new medicines and their counterparts, to collect patent challenges against new medicines, and to calculate effective market exclusivity for new medicines. Then, a nonparametric event history model was applied to statistically explain the duration of the market exclusivity of new medicines. Between 2007 and 2011, a total of 94 new medicines, consisting of 82 new chemical entities and 12 new biologics, were approved. The patent linkage system encouraged patent litigations to occur sooner, with a race to challenge the patents by various generic applicants. However, it was difficult to conclude that patent challenges had a significant impact on the prolongation of effective market exclusivity. The patent linkage system had a neutral effect on the effective market exclusivity of new medicines and encouraged patent challenges without abbreviating effective market exclusivity. In addition, this study highlights an important issue regarding biologics that has not been the subject of market competition, even for patent challenges. © The Author(s) 2019. | - |
dc.format.extent | 16 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Baywood Publishing Co., Inc. | - |
dc.title | Does the Patent Linkage System Prolong Effective Market Exclusivity? Recent Evidence From the Korea-US Free Trade Agreement in Korea | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1177/0020731418822237 | - |
dc.identifier.scopusid | 2-s2.0-85060020801 | - |
dc.identifier.wosid | 000461624400008 | - |
dc.identifier.bibliographicCitation | International Journal of Health Services, v.49, no.2, pp 306 - 321 | - |
dc.citation.title | International Journal of Health Services | - |
dc.citation.volume | 49 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 306 | - |
dc.citation.endPage | 321 | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Health Policy & Services | - |
dc.subject.keywordPlus | CHALLENGES | - |
dc.subject.keywordPlus | ACCESS | - |
dc.subject.keywordAuthor | free trade agreements | - |
dc.subject.keywordAuthor | linkage | - |
dc.subject.keywordAuthor | market exclusivity | - |
dc.subject.keywordAuthor | patent challenge | - |
dc.subject.keywordAuthor | patent linkage | - |
dc.identifier.url | https://www.scopus.com/record/display.uri?eid=2-s2.0-85060020801&origin=inward&txGid=693d4449d220304f5231403795be9873 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.